Table of Content

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in autoimmune dealmaking

2.1. Introduction
2.2. Autoimmune partnering over the years
2.3. Autoimmune partnering by deal type
2.4. Autoimmune partnering by industry sector
2.5. Autoimmune partnering by stage of development
2.6. Autoimmune partnering by technology type

Chapter 3 –Financial deal terms for autoimmune partnering

3.1. Introduction
3.2. Disclosed financials terms for autoimmune partnering
3.3. Autoimmune partnering headline values
3.4. Autoimmune deal upfront payments
3.5. Autoimmune deal milestone payments
3.6. Autoimmune royalty rates

Chapter 4 – Leading autoimmune deals and dealmakers

4.1. Introduction
4.2. Most active in autoimmune partnering
4.3. List of most active dealmakers in autoimmune
4.4. Top autoimmune deals by value

Chapter 5 – Autoimmune contract document directory

5.1. Introduction
5.2. Autoimmune partnering deals where contract document available

Chapter 6 – Autoimmune dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by autoimmune therapeutic target

Appendices

Appendix 1 – Directory of autoimmune deals by company A-Z 2016 to 2023
Appendix 2 – Directory of autoimmune deals by deal type 2016 to 2023
Appendix 3 – Directory of autoimmune deals by stage of development 2016 to 2023
Appendix 4 – Directory of autoimmune deals by technology type 2016 to 2023
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

Table of figures

Figure 1: Autoimmune partnering since 2016
Figure 2: Autoimmune partnering by deal type since 2016
Figure 3: Autoimmune partnering by industry sector since 2016
Figure 4: Autoimmune partnering by stage of development since 2016
Figure 5: Autoimmune partnering by technology type since 2016
Figure 6: Autoimmune deals with a headline value
Figure 7: Autoimmune deals with upfront payment values
Figure 8: Autoimmune deals with milestone payment
Figure 9: Autoimmune deals with royalty rates
Figure 10: Active autoimmune dealmaking activity– 2016 to 2023
Figure 11: Top autoimmune deals by value since 2016